Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Sep 24;7(9):e018035.
doi: 10.1136/bmjopen-2017-018035.

COBI (COntinuous hyperosmolar therapy for traumatic Brain-Injured patients) trial protocol: a multicentre randomised open-label trial with blinded adjudication of primary outcome

Antoine Roquilly  1 , Sigismond Lasocki  2 , Jean Denis Moyer  3 , Olivier Huet  4 , Pierre François Perrigault  5 , Claire Dahyot-Fizelier  6 , Philippe Seguin  7 , Tarek Sharshar  8 , Thomas Geeraerts  9 , Francis Remerand  10 , Fanny Feuillet  11   12 , Karim Asehnoune  1 ; COBI group
Affiliations
Randomized Controlled Trial

COBI (COntinuous hyperosmolar therapy for traumatic Brain-Injured patients) trial protocol: a multicentre randomised open-label trial with blinded adjudication of primary outcome

Antoine Roquilly et al. BMJ Open. .

Abstract

Introduction: Traumatic brain injury (TBI) is a major cause of death and severe prolonged disability. Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after TBI. Continuous infusion of hyperosmolar therapy has been proposed for the prevention and the treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves long-term outcomes of patients with TBI is uncertain. The aim of the COBI study (number clinicaltrial.gov 03143751, pre-results stage) is to assess the efficiency and the safety of continuous hyperosmolar therapy in patients with TBI.

Methods and analysis: The COBI (COntinuous hyperosmolar therapy in traumatic Brain-Injured patients) trial is a multicentre, randomised, controlled, open-label, two-arms study with blinded adjudication of primary outcome. Three hundred and seventy patients hospitalised in intensive care unit with a TBI (Glasgow Coma Scale ≤12 and abnormal brain CT scan) are randomised in the first 24 hours following trauma to standard care or continuous hyperosmolar therapy (20% NaCl) plus standard care. Continuous hyperosmolar therapy is maintained for at least 48 hours in the treatment group and continued for as long as is necessary to prevent ICH. The primary outcome is the score on the Extended Glasgow Outcome Scale at 6 months. The treatment effect is estimated with ordinal logistic regression adjusted for prespecified prognostic factors and expressed as a common OR.

Ethics and dissemination: The COBI trial protocol has been approved by the ethics committee of Paris Ile de France VIII and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentation at scientific conferences and publication in peer-reviewed journals. The COBI trial is the first randomised controlled trial powered to investigate whether continuous hyperosmolar therapy in patients with TBI improve long-term recovery.

Trial registration number: Trial registration number is NCT03143751.

Keywords: brain oedema; hyperosmolar therapy; hypertonic; intracranial hypertension; saline solution; sodium; trauma; traumatic brain injury.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Protocol for the dose adaptation of the continuous hyperosmolar therapy.
Figure 2
Figure 2
Stages of therapeutic management and trial follow-up. FIM, functional independence measure; GOAT, Galveston Orientation and Amnesia Test; GOS-E, Extended Glasgow Outcome Scale; ICH, intracranial hypertension; SF-36, Short Form 36.
See this image and copyright information in PMC

References

    1. Mokdad AH, Forouzanfar MH, Daoud F, et al. . Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2016;387:2383–401. 10.1016/S0140-6736(16)00648-6 - DOI - PubMed
    1. Sandhaug M, Andelic N, Langhammer B, et al. . Functional level during the first 2 years after moderate and severe traumatic brain injury. Brain Inj 2015;29:1431–8. 10.3109/02699052.2015.1063692 - DOI - PubMed
    1. Olesen J, Gustavsson A, Svensson M, et al. . The economic cost of brain disorders in Europe. Eur J Neurol 2012;19:155–62. 10.1111/j.1468-1331.2011.03590.x - DOI - PubMed
    1. Asehnoune K, Seguin P, Allary J, et al. . Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med 2014;2:706–16. 10.1016/S2213-2600(14)70144-4 - DOI - PubMed
    1. Asehnoune K, Mrozek S, Perrigault PF, et al. . A multi-faceted strategy to reduce ventilation-associated mortality in brain-injured patients. The BI-VILI project: a nationwide quality improvement project. Intensive Care Med 2017;43:957–70. 10.1007/s00134-017-4764-6 - DOI - PubMed

Publication types

MeSH terms

Associated data